Clinical trials: Cervical Adenocarcinoma
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
Papillary Thyroid Cancer
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
Oxidative stress (OS) could be involved in the progression of papillary thyroid cancer (PTC). Indeed, thyroid differentiation genes are silenced by a mechanism controlled by NOX4-derived OS.
- Trial name
- TEMPEST (NCT05752669)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Istituto Auxologico Italiano
Hepatocellular Cancer, Cholangiocarcinoma
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
PLATON (Platform for Analyzing Targetable Mutations) is a prospective, multicentre, observational cohort study with biobanking. In a first approach PLATON's pilot-study assesses genomic profiling in gastrointestinal cancer…
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- PLATON (NCT04484636)
- Testing
- FoundationOne®CDx and FoundationOne®Liquid
- Where
- 46 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Breast Cancer, Colorectal Cancer
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00622674
- Testing
- cetuximab, bortezomib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Esophageal Cancer
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00004897
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Sponsor
- Northwestern University
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Cervix, Adenocarcinoma of the Cervix
Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application
They include patients who are candidates to complete concurrent treatment with endocavitary brachytherapy External radiation therapy + more QT based weekly cisplatin.
- Trial name
- NCT01639625
- Testing
- CIGB300
- Where
- Argentina
- Volunteers
- 18 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
This is a phase 1b/2, open-label, two-part, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod injections alone and in…
- Conditions
- Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03684785
- Testing
- Cavrotolimod, Pembrolizumab, Cemiplimab
- Where
- 26 sites in United States
- Volunteers
- 57 people
- Sponsor
- Exicure, Inc.
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers.
- Conditions
- Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT01846520
- Testing
- educational intervention, telephone-based intervention, quality-of-life assessment
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Head and Neck Neoplasms, Pheochromocytoma
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Background: The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00923481
- Testing
- Fostamatinib disodium
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Thyroid Cancer
Pharmaceutical Management in Targeted Radioligand Therapy
Targeted Radionuclide Therapy (TRT) is a treatment modality used in nuclear medicine to target cancer cells while preserving surrounding healthy tissues.
- Conditions
- Cancer, Thyroid Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumor Carcinoid
- Trial name
- PharmTRT (NCT07389512)
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Hospices Civils de Lyon
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Papillary Thyroid Cancer, Follicular Thyroid Cancer
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
This study is comparing a drug called Sutent with standard of care treatment for people with advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and effective treatment options are limited…
- Conditions
- Papillary Thyroid Cancer, Follicular Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- IIT Sutent (NCT00668811)
- Testing
- SU011248, Sutent
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medstar Health Research Institute
Esophageal Cancer
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00066716
- Testing
- carboplatin, celecoxib, paclitaxel
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Weill Medical College of Cornell University
Cervical Cancer
Radiation Therapy in Treating Patients With Cervical Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00278304
- Testing
- brachytherapy, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
- Conditions
- Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04681248
- Testing
- DKN-01
- Where
- 5 sites in United States
- Sponsor
- Leap Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.